Factors associated with the suboptimal treatment of women less than 55 years of age with early-stage ovarian cancer

Gynecologic Oncology

Volumn 108, Issue 1, 2008, Pages 95-99

  Chan, John K ^a   Kapp, Daniel S ^b   Shin, Jacob Y ^a   Osann, Kathryn ^c   Leiserowitz, Gary S ^d   Cress, Rosemary D ^e   O'Malley, Cynthia ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e California Cancer Registry   (United States)

^f NORTHERN CALIFORNIA CANCER CENTER   (United States)

Author keywords

Chemotherapy; Ovarian cancer; Younger women

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DATA ANALYSIS; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE;

ADULT; AGE FACTORS; CHEMOTHERAPY, ADJUVANT; EPITHELIAL CELLS; FEMALE; GUIDELINE ADHERENCE; GYNECOLOGY; HEALTH SERVICES ACCESSIBILITY; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RISK FACTORS; SOCIOECONOMIC FACTORS; SURVIVAL RATE;

EID: 37448999868     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.08.087     Document Type: Article

References (34)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Hoskins P.J., Swenerton K.D., Manji M., et al. 'Moderate-risk' ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation. Int J Gynecol Cancer 4 (1994) 272-278
3. Partridge E.E., Phillips J.L., and Menck H.R. The National Cancer Data Base report on ovarian cancer treatment in United States hospitals. Cancer 78 (1996) 2236-2246
4. Heintz A.P., Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. Int J Gynaecol Obstet 83 Suppl 1 (2003) 135-166
5. Averette H.E., Janicek M.F., and Menck H.R. The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 76 (1995) 1096-1103
6. Kosary C.L. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 10 (1994) 31-46
7. Janssen-Heijnen M.L., Houterman S., Lemmens V.E., et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 55 (2005) 231-240
8. Sundararajan V., Hershman D., Grann V.R., et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 20 (2002) 173-178
9. Hutchins L.F., Unger J.M., Crowley J.J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341 (1999) 2061-2067
10. Parham G., Phillips J.L., Hicks M.L., et al. The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women. Cancer 80 (1997) 816-826
11. Goff B.A., Matthews B.J., Wynn M., et al. Ovarian cancer: patterns of surgical care across the United States. Gynecol Oncol 103 (2006) 383-390
12. Cress R.D., O'Malley C.D., Leiserowitz G.S., et al. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol 21 (2003) 1530-1535
13. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 82 (1992) 703-710
14. O'Malley C.D., Cress R.D., Campleman S.L., et al. Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol 91 (2003) 608-615
15. SPSS, Inc. Chicago, IL, 2006.
16. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer 1, 2007: National Comprehensive Cancer Network (2007)
17. Young R.C., Walton L.A., Ellenberg S.S., et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322 (1990) 1021-1027
18. Trimbos J.B., Vergote I., Bolis G., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95 (2003) 113-125
19. Colombo N., Guthrie D., Chiari S., et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95 (2003) 125-132
20. Nguyen H.N., Averette H.E., Hoskins W., et al. National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 72 (1993) 3007-3011
21. Kolomainen D.F., A'Hern R., Coxon F.Y., et al. Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy?. J Clin Oncol 21 (2003) 3113-3118
22. Carney M.E., Lancaster J.M., Ford C., et al. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?. Gynecol Oncol 84 (2002) 36-42
23. Noumoff J., Morgan M., King S., et al. The specialty of gynecologic oncology as perceived by the public. Gynecol Oncol 47 (1992) 48-52
24. Le T., Adolph A., Krepart G.V., et al. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 85 (2002) 351-355
25. Harlan L.C., Abrams J., Warren J.L., et al. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol 20 (2002) 1809-1817
26. Schrag D., Earle C., Xu F., et al. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst 98 (2006) 163-171
27. Chan J.K., Kapp D.S., Shin J.Y., et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol 109 6 (June 2007) 1342-1350
28. Eisenkop S.M., Spirtos N.M., Montag T.W., et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 47 (1992) 203-209
29. Nguyen H.N., Averette H.E., Hoskins W., et al. National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer 72 (1993) 3663-3670
30. Kehoe S., Powell J., Wilson S., et al. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer 70 (1994) 1014-1017
31. Earle C.C., Schrag D., Neville B.A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98 (2006) 172-180
32. Engelen M.J., Kos H.E., Willemse P.H., et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106 (2006) 589-598
33. Giede K.C., Kieser K., Dodge J., et al. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 99 (2005) 447-461
34. Munstedt K., von Georgi R., Misselwitz B., et al. Centralizing surgery for gynecologic oncology-a strategy assuring better quality treatment?. Gynecol Oncol 89 (2003) 4-8